|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Rivaroxaban#Contraindications]] |
| {{Rivaroxaban}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Contraindications==
| | [[Category: Cardiovascular Drugs]] |
| XARELTO is contraindicated in patients with:
| | [[Category: Drug]] |
| | |
| *active pathological bleeding [see [[Rivaroxaban warnings and precautions |Warnings and Precautions]] (5.2)]
| |
| | |
| *severe hypersensitivity reaction to XARELTO (e.g., [[anaphylactic reactions]]) [see [[Rivaroxaban adverse reactions |Adverse Reactions]] (6.2)] <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = XARELTO (RIVAROXABAN) TABLET, FILM COATED [JANSSEN PHARMACEUTICALS, INC.] |url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]] | |